Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chroma/CTI plan tosedostat PhIII to avoid AML trap that caught Vion, J&J and Genzyme

This article was originally published in Scrip

Executive Summary

The mood of de-risking that prevails in the life sciences at the moment means that the transition of its lead compound tosedostat from Phase II studies to two Phase III registrational trials for acute myeloid leukaemia (AML) in 2012 is a crucial step for Chroma Therapeutics, the UK-based originator of the molecule and for Cell Therapeutics Inc., Chroma's US-based licensee for the Americas (North, South and Central).

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC015543

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel